Document Detail

Two-year analysis of efficacy and safety of deferasirox treatment for transfusional iron overload in sickle cell anemia patients.
MedLine Citation:
PMID:  22760067     Owner:  NLM     Status:  MEDLINE    
The efficacy and safety of a 2-year treatment with deferasirox was evaluated in 31 patients with sickle cell anemia and transfusional iron overload. At 24 months, there were significant decreases from baseline in mean serum ferritin (from 2,344.6 to 1,986.3 µg/l; p = 0.040) and in mean liver iron concentration (from 13.0 ± 5.4 to 9.3 ± 5.7 mg Fe/g dry weight; p < 0.001). Myocardial T2* values were normal (>20 ms) in all patients at baseline and did not change significantly over the course of the study. However, there was a significant improvement from baseline in left ventricular ejection fraction at 24 months (62.2-64.6%; p = 0.02). Deferasirox was generally well tolerated with no progressive increases in serum creatinine or renal failure observed. These data confirm that deferasirox is effective in reducing body iron burden in patients with sickle cell anemia and transfusional iron overload.
Rodolfo Cancado; Maria Cristina A Olivato; Paula Bruniera; Gilberto Szarf; Roberto de Moraes Bastos; Murilo Rezende Melo; Carlos Chiattone
Related Documents :
7605147 - The rationale for continuous maintenance treatment of reflux esophagitis.
17090277 - Comparison of esophageal acid exposure distribution along the esophagus among the diffe...
17646787 - Prevalence and topography of intestinal metaplasia in columnar lined esophagus.
7325147 - Irreversible esophageal motor dysfunction in postvagotomy dysphagia.
11431177 - Renal lesions in leprosy: a retrospective study of 199 autopsies.
22393317 - Increased orienting to unexpected action outcomes in schizophrenia.
Publication Detail:
Type:  Clinical Trial, Phase IV; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-06-30
Journal Detail:
Title:  Acta haematologica     Volume:  128     ISSN:  1421-9662     ISO Abbreviation:  Acta Haematol.     Publication Date:  2012  
Date Detail:
Created Date:  2012-08-21     Completed Date:  2012-10-23     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0141053     Medline TA:  Acta Haematol     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  113-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Department of Hematology/Oncology, Santa Casa Medical School, São Paulo, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anemia, Sickle Cell / drug therapy*
Benzoates / adverse effects,  therapeutic use*
Iron Chelating Agents / adverse effects,  therapeutic use*
Iron Overload / drug therapy*
Prospective Studies
Triazoles / adverse effects,  therapeutic use*
Young Adult
Reg. No./Substance:
0/Benzoates; 0/Iron Chelating Agents; 0/Triazoles; V8G4MOF2V9/deferasirox

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Redox-related antimelanoma activity of ATN-224.
Next Document:  In vitro measurements of tracheal constriction using mice.